Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Celsion Corporation    CLSN

CELSION CORPORATION

(CLSN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Celsion Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

11/03/2020 | 03:47pm EST

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Celsion Corporation (“Celsion” or “the Company”) (NASDAQ: CLSN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between November 2, 2015 and July 10, 2020, inclusive (the ''Class Period''), are encouraged to contact the firm before December 29, 2020.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Celsion considerably overstated the efficacy of its ThermoDox product. This lack of efficacy negatively impacted the Company’s likelihood of gaining approval for ThermoDox. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Celsion, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.


© Business Wire 2020
All news about CELSION CORPORATION
01/25CELSION CORP : Entry into a Material Definitive Agreement, Other Events, Financi..
AQ
01/22MIDDAY REPORT : Wall Street Drifts Lower Midday as IBM, Intel Slump
MT
01/22CELSION : to Raise $35 Million in Registered Direct Offering of Common Stock
MT
01/22Celsion corporation announces $35 million registered direct offering priced a..
GL
01/21CELSION CORP : Termination of a Material Definitive Agreement (form 8-K)
AQ
2020CELSION CORP : Change in Directors or Principal Officers (form 8-K)
AQ
2020DEADLINE TODAY : The Schall Law Firm Announces it is Investigating Claims Agains..
BU
2020CELSION : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
2020CELSION CORP : Results of Operations and Financial Condition, Financial Statemen..
AQ
2020CELSION CORPORATION : Reports Third Quarter 2020 Financial Results and Provides ..
AQ
More news
Financials (USD)
Sales 2020 0,50 M - -
Net income 2020 -23,3 M - -
Net Debt 2020 - - -
P/E ratio 2020 -1,92x
Yield 2020 -
Capitalization 52,4 M 52,4 M -
Capi. / Sales 2020 105x
Capi. / Sales 2021 -
Nbr of Employees 29
Free-Float 99,9%
Chart CELSION CORPORATION
Duration : Period :
Celsion Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELSION CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Average target price 3,00 $
Last Close Price 1,40 $
Spread / Highest target 114%
Spread / Average Target 114%
Spread / Lowest Target 114%
EPS Revisions
Managers and Directors
NameTitle
Michael H. Tardugno Chairman, President & Chief Executive Officer
Jeffrey Wayne Church CFO, Secretary & SVP-Investor Relations
Nicholas Borys Chief Medical Officer & Senior Vice President
Khursheed Anwer Chief Scientific Officer & Executive VP
Pok Yu Chow Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CELSION CORPORATION96.91%52
GILEAD SCIENCES, INC.16.99%85 440
WUXI APPTEC CO., LTD.36.65%68 869
VERTEX PHARMACEUTICALS2.10%62 750
REGENERON PHARMACEUTICALS13.47%57 859
BEIGENE, LTD.45.87%34 368